Ping Chi
About
Ping Chi is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Oncology.
According to data from OpenAlex, Ping Chi has authored 145 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Pulmonary and Respiratory Medicine, 46 papers in Gastroenterology and 45 papers in Oncology. Recurrent topics in Ping Chi's work include Gastrointestinal Tumor Research and Treatment (46 papers), Sarcoma Diagnosis and Treatment (45 papers) and Gastric Cancer Management and Outcomes (24 papers). Ping Chi is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (46 papers), Sarcoma Diagnosis and Treatment (45 papers) and Gastric Cancer Management and Outcomes (24 papers). Ping Chi collaborates with scholars based in United States, China and United Kingdom. Ping Chi's co-authors include C. David Allis, Gang Greg Wang, Timothy A. Ryan, Paul Greengard, Cristina R. Antonescu, Yu Chen, Ciara M. Kelly, William D. Tap, Mrinal M. Gounder and Sandra P. D’Angelo and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Nature Medicine.
In The Last Decade
Ping Chi
137 papers receiving 5.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ping Chi United States | 35 | 2.8k | 1.8k | 1.1k | 924 | 607 | 145 | 5.9k | ||
| Hans Scherübl Germany | 45 | 2.3k 0.8× | 560 0.3× | 2.0k 1.8× | 263 0.3× | 676 1.1× | 154 | 5.3k | ||
| Brian Zambrowicz United States | 42 | 3.4k 1.2× | 193 0.1× | 818 0.7× | 184 0.2× | 1.3k 2.2× | 82 | 6.8k | ||
| François Paris France | 36 | 3.1k 1.1× | 1.2k 0.7× | 1.2k 1.1× | 71 0.1× | 484 0.8× | 90 | 6.3k | ||
| Ole B. Suhr Sweden | 51 | 7.3k 2.6× | 402 0.2× | 1.6k 1.4× | 353 0.4× | 950 1.6× | 234 | 9.0k | ||
| Sanjay Jain United States | 42 | 3.1k 1.1× | 777 0.4× | 877 0.8× | 49 0.1× | 1.0k 1.7× | 162 | 7.0k | ||
| Takeshi Kato Japan | 35 | 1.2k 0.4× | 680 0.4× | 2.1k 1.9× | 69 0.1× | 559 0.9× | 294 | 4.2k | ||
| Takao Takahashi Japan | 33 | 2.6k 0.9× | 1.0k 0.6× | 1.6k 1.5× | 48 0.1× | 394 0.6× | 189 | 5.1k | ||
| Katya Ravid United States | 51 | 2.8k 1.0× | 385 0.2× | 631 0.6× | 76 0.1× | 595 1.0× | 174 | 6.8k | ||
| Arthur Sands United States | 35 | 4.0k 1.4× | 208 0.1× | 2.1k 1.9× | 90 0.1× | 943 1.6× | 62 | 6.5k | ||
| Gregory M. Springett United States | 30 | 1.9k 0.7× | 836 0.5× | 2.0k 1.8× | 57 0.1× | 613 1.0× | 86 | 4.4k |
Countries citing papers authored by Ping Chi
Since
Specialization
Citations
This map shows the geographic impact of Ping Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ping Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ping Chi more than expected).
Fields of papers citing papers by Ping Chi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ping Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ping Chi. The network helps show where Ping Chi may publish in the future.
Co-authorship network of co-authors of Ping Chi
This figure shows the co-authorship network connecting the top 25 collaborators of Ping Chi. A scholar is included among the top collaborators of Ping Chi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ping Chi. Ping Chi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kelly, Ciara M., Mary Louise Keohan, Jason E. Chan, et al.. (2024). 1752P A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma. Annals of Oncology. 35. S1045–S1045.
2.
Dickson, Mark A., Sujana Movva, Ciara M. Kelly, et al.. (2024). 1720MO A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma. Annals of Oncology. 35. S1031–S1031.
3.
Chandana, Sreenivasa R, Dale R. Shepard, Janice M. Mehnert, et al.. (2024). DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.. Journal of Clinical Oncology. 42(16_suppl). TPS11587–TPS11587.
4.
Ran, Leili, Amish J. Patel, Juan Yan, et al.. (2024). MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. Clinical Cancer Research. 30(22). 5154–5165.
5.
Huang, Xinxin, Xingyu Chen, Xiu Chen, et al.. (2023). Sound touch elastography of Achilles tendons in patients with type 2 diabetes mellitus versus healthy adults. Diabetology & Metabolic Syndrome. 15(1). 174–174.
6.
Dermawan, Josephine K., Ciara M. Kelly, Zhidong Gao, et al.. (2023). Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era. Clinical Cancer Research. 29(19). 3974–3985.
7.
Mandelker, Diana, Antonio Marra, Nikita Mehta, et al.. (2023). Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. npj Precision Oncology. 7(1).
8.
Yu, Kunpeng, Zhipeng Zhang, Ping Chi, et al.. (2023). Highly efficient phosphorescent organic light-emitting diodes with low turn-on voltages using N-phenylcarbazole/pyrimidine-based bipolar host materials. Dyes and Pigments. 222. 111828–111828.
9.
Rosenbaum, Evan, Kenneth Seier, Martina Bradić, et al.. (2023). Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas. Cancer Research Communications. 3(10). 2118–2125.
10.
Chi, Ping, et al.. (2022). [Historical evolution and ultimate goal of minimally invasive surgery for colorectal cancer].. PubMed. 25(8). 675–681.
11.
Bartlett, Edmund K., Kenneth Seier, Cristina R. Antonescu, et al.. (2022). Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma. JCO Precision Oncology. 6(6). e2200087–e2200087.
12.
George, Suzanne, Ping Chi, Michael C. Heinrich, et al.. (2021). Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. European Journal of Cancer. 155. 236–244.
13.
Bauer, Sebastian, Michael C. Heinrich, Suzanne George, et al.. (2021). Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clinical Cancer Research. 27(23). 6333–6342.
14.
Rosenbaum, Evan, Kenneth Seier, Chaitanya Bandlamudi, et al.. (2020). HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research. 26(20). 5448–5455.
15.
Song, Jiacheng, Zhixin Chen, David Huang, et al.. (2020). Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy. SHILAP Revista de lepidopterología.
16.
Ceraudo, Emilie, Tyler D. Hitchman, Amanda R. Moore, et al.. (2020). Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. Journal of Biological Chemistry. 296. 100163–100163.
17.
Zhao, Xu, Ying Zhang, Ming-Qing Xu, et al.. (2019). Demethylation and Overexpression of CSF2 are Involved in Immune Response, Chemotherapy Resistance, and Poor Prognosis in Colorectal Cancer. SHILAP Revista de lepidopterología.
18.
Ran, Leili, Devan Murphy, Jessica Sher, et al.. (2017). ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors. Cancer Research. 77(14). 3758–3765.
19.
D’Angelo, Sandra P., Alexander N. Shoushtari, Mary Louise Keohan, et al.. (2016). Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research. 23(12). 2972–2980.
20.
Ran, Leili, Inna Sirota, Zhen Cao, et al.. (2015). Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. Cancer Discovery. 5(3). 304–315.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hans Scherübl Breakdown of academic impact, for papers by Brian Zambrowicz Breakdown of academic impact, for papers by François Paris Breakdown of academic impact, for papers by Ole B. Suhr Breakdown of academic impact, for papers by Sanjay Jain Breakdown of academic impact, for papers by Takeshi Kato Breakdown of academic impact, for papers by Takao Takahashi Breakdown of academic impact, for papers by Katya Ravid Breakdown of academic impact, for papers by Arthur Sands Breakdown of academic impact, for papers by Gregory M. Springett